Abstract
Background
Our aim was to investigate the disease-free survival in patients with tongue squamous cell carcinoma receiving metronomic neoadjuvant chemotherapy with 5-fluorouracil prodrugs (UFT or S-1) plus bleomycin compared with those who had up-front surgery retrospectively.
Methods
In this retrospective study, 108 patients with stages I to II tongue squamous cell carcinoma who had undergone surgery were divided into the “surgery group” or “neoadjuvant chemotherapy group.”
Results
A total of 41 patients received up-front surgery; 67 received metronomic neoadjuvant chemotherapy with UFT plus bleomycin (39) or S-1 plus bleomycin (28). The rate of disease-free survival was the primary outcome measure. Neoadjuvant 5-fluorouracil prodrugs did not correlate higher with improved disease-free survival than up-front surgery (72 and 54%, respectively; hazard ratio for recurrence or death, 0.54; 95% confidence interval [CI], 0.28 to 1.03; P = 0.06). Patients who received S-1 were more likely than those who received UFT to have pathological complete response (46% vs. 15%; P = 0.007). Neoadjuvant S-1 significantly improved disease-free survival as compared with up-front surgery (79% vs. 54%; hazard ratio, 0.41; 95% CI, 0.15 to 0.98; P = 0.04). However, neoadjuvant UFT did not improve disease-free survival as compared with up-front surgery (67% vs. 54%, respectively; hazard ratio, 0.66; 95% CI, 0.31 to 1.33; P = 0.24).
Conclusions
Neoadjuvant S-1 chemotherapy, as compared with up-front surgery, significantly improved disease-free survival among patients with tongue squamous cell carcinoma.
Clinical relevance
A choice of drugs before neoadjuvant metronomic chemotherapy is needed.
Similar content being viewed by others
References
De Felice F, Musio D, Tombolini V (2015) Head and neck cancer: metronomic chemotherapy. BMC Cancer 15:677
Kina S, Nakasone T, Kinjo T, Maruyama T, Kawano T, Arasaki A (2016) Impact of metronomic neoadjuvant chemotherapy on early tongue cancer. Cancer Chemother Pharmacol 78:833–840
André N, Carré M, Pasquier E (2014) Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 11:413–431
Patil VM, Noronha V, Joshi A, Muddu VK, Dhumal S, Bhosale B et al (2015) A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol 51(3):279–286
Adjei AA (1999) A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 48(3):265–277
Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H et al (2010) 5-Fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers (Basel) 2(3):1717–1730
Takechi T, Fujioka A, Matsushima E, Fukushima M (2002) Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38(9):1271–1277
Nishimura G, Yanoma S, Mizuno H, Satake K, Taguchi T, Ikeda Y et al (2000) Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells. Cancer Lett 159:1–7
Huang SF, Kang CJ, Lin CY, Fan KH, Yen TC, Wang HM, Chen IH, Liao CT, Cheng AJ, Chang JTC (2008) Neck treatment of patients with early stage oral tongue cancer: Comparison between observation, supraomohyoid dissection, and extended dissection. Cancer 112(5):1066–1075
Fletcher AM, Heaford AC, Trask DK (2008) Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific mir-205. Transl Oncol 1(4):202–208
Sasaki M, Aoki T, Karakida K, Otsuru M, Takahashi M, Akamatsu T, Sakamoto H, Ota Y (2011) Postoperative follow-up strategy in patients with oral squamous cell carcinoma. J Oral Maxillofac Surg 69(6):e105–e111
Kawashiri S, Noguchi N, Tanaka A, Nakaya H, Kato K, Yamamoto E (2009) Inhibitory effect of neoadjuvant chemotherapy on metastasis of oral squamous cell carcinoma in a mouse model. Oral Oncol 45(9):794–797
Tsukahara K, Kubota A, Hasegawa Y, Takemura H, Terada T, Taguchi T et al (2015) Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC). PLoS One 10:e0116965
Atula TS, Varpula MJ, Kurki TJ, Klemi PJ, Grénman R (1997) Assessment of cervical lymph node status in head and neck cancer patients: palpation, computed tomography and low field magnetic resonance imaging compared with ultrasound-guided fine-needle aspiration cytology. Eur J Radiol 25:152–161
Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I et al (2014) Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica 99(5):930–936
Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL et al (2004) Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15(5):1307–1315
Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I (2004) Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 328(7446):983
Tsukuda M, Miyake H (2000) Maintenance chemotherapy with UFT for head and neck carcinoma. Oncology 14:93–95
Lam P, Yuen AP, Ho CM, Ho WK, Wei WI (2001) Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma. Eur J Surg Oncol 27:750–753
Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436
Scharovsky OG, Mainetti LE, Rozados VR (2009) Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 16:7–15
Grégoire V, Beauduin M, Humblet Y, Hamoir M, Longueville J, Majois F et al (1991) A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium. J Clin Oncol 9:1385–1392
Ferdous T, Harada K, Kin T, Harada T, Ueyama Y (2013) Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells. Int J Oncol 43:271–279
Rusthoven K, Ballonoff A, Raben D, Chen C (2008) Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer 112:345–351
Murthy V, Agarwal JP, Laskar SG, Gupta T, Budrukkar A, Pai P et al (2010) Analysis of prognostic factors in 1180 patients with oral cavity primary cancer treated with definitive or adjuvant radiotherapy. J Cancer Res Ther 6:282–289
Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, Shedd DP (1987) Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 154:439–442
Wong SY, Hynes RO (2006) Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle 5(8):812–817
Sano D, Myers JN (2007) Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26:645–662
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127
Hsieh MY, Chen G, Chang DC, Chien SY, Chen MK (2018) The impact of metronomic adjuvant chemotherapy in patients with advanced oral cancer. Ann Surg Oncol 25(7):2091–2097
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
All procedures performed were in accordance with the ethics committee at the University of the Ryukyus (No. 772), and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
We treated the patients at the Department of Oral and Maxillofacial Surgery, and all patients provided written informed consent.
Rights and permissions
About this article
Cite this article
Kina, S., Nakasone, T., Kinjo, T. et al. Outcomes after up-front surgery and metronomic neoadjuvant chemotherapy with S-1 or UFT for early tongue squamous cell carcinoma. Clin Oral Invest 23, 2593–2598 (2019). https://doi.org/10.1007/s00784-018-2689-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00784-018-2689-2